-
2-{[3-(4-chlorophenyl)-3-[4-(1,3-thiazole-2-carbonyl)phenoxy]propyl](methyl)amino}acetic acid hydrate hydrochloride
-
ChemBase ID:
154734
-
Molecular Formular:
C22H24Cl2N2O5S
-
Molecular Mass:
499.40736
-
Monoisotopic Mass:
498.07829824
-
SMILES and InChIs
SMILES:
CN(CCC(c1ccc(cc1)Cl)Oc1ccc(cc1)C(=O)c1nccs1)CC(=O)O.O.Cl
Canonical SMILES:
CN(CC(=O)O)CCC(c1ccc(cc1)Cl)Oc1ccc(cc1)C(=O)c1nccs1.O.Cl
InChI:
InChI=1S/C22H21ClN2O4S.ClH.H2O/c1-25(14-20(26)27)12-10-19(15-2-6-17(23)7-3-15)29-18-8-4-16(5-9-18)21(28)22-24-11-13-30-22;;/h2-9,11,13,19H,10,12,14H2,1H3,(H,26,27);1H;1H2
InChIKey:
CVQXAUBKPDYXHF-UHFFFAOYSA-N
-
Cite this record
CBID:154734 http://www.chembase.cn/molecule-154734.html
NAMES AND DATABASE IDS
NAMES AND DATABASE IDS
Names Database IDs
IUPAC name
|
2-{[3-(4-chlorophenyl)-3-[4-(1,3-thiazole-2-carbonyl)phenoxy]propyl](methyl)amino}acetic acid hydrate hydrochloride
|
|
|
IUPAC Traditional name
|
{[3-(4-chlorophenyl)-3-[4-(1,3-thiazole-2-carbonyl)phenoxy]propyl](methyl)amino}acetic acid hydrate hydrochloride
|
|
|
Synonyms
|
({3-(4-Chlorophenyl)-3-[4-(thiazole-carbonyl)-phenoxy]-propyl}-methyl-amino)-acetic acid hydrochloride hydrate
|
N-[3-(4-Chlorophenyl)-3-[4-(2-thiazolylcarbonyl)phenoxy]propyl]-N-methyl-glycine hydrochloride hydrate
|
CP-802079 hydrochloride hydrate
|
|
|
CAS Number
|
|
MDL Number
|
|
PubChem SID
|
|
PubChem CID
|
|
DATA SOURCES
DATA SOURCES
All Sources Commercial Sources Non-commercial Sources
CALCULATED PROPERTIES
CALCULATED PROPERTIES
JChem
Acid pKa
|
1.1916847
|
H Acceptors
|
6
|
H Donor
|
1
|
LogD (pH = 5.5)
|
1.5264492
|
LogD (pH = 7.4)
|
1.5177597
|
Log P
|
1.5264868
|
Molar Refractivity
|
115.839 cm3
|
Polarizability
|
45.025223 Å3
|
Polar Surface Area
|
79.73 Å2
|
Rotatable Bonds
|
10
|
Lipinski's Rule of Five
|
true
|
DETAILS
DETAILS
Sigma Aldrich
Sigma Aldrich -
PZ0148
|
Legal Information Sold for research purposes under agreement from Pfizer Inc. Biochem/physiol Actions CP-802079 is a potent and selective glycine transporter type 1 (GlyT1) antagonist. Antagonists of GlyT1 increase levels of glycine in the synaptic cleft and, like direct glycine site agonists, they can augment NMDAR currents and NMDAR-mediated functions. CP-802,079 significantly increases the amplitude of the NMDAR currents and LTP. |
PATENTS
PATENTS
PubChem Patent
Google Patent